FRCPC

RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit

Retrieved on: 
Monday, October 18, 2021
Risk, Cancer, Security (finance), Inflammation, CCR4, Patient, GLOBE, Research, U.S. Securities and Exchange Commission, Forward-looking statement, SAN, Company, RAPT, MD, Therapy, Medical director, FRCPC, Atopic dermatitis, Pharmaceutical industry

Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases.

Key Points: 
  • Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases.
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.
  • Forward-looking statements include, but are not limited to, statements about the progress of RAPTs oncology and inflammation programs and the interpretation of topline results from the Phase 1b trial of RPT193.
  • RAPT disclaims any obligation to update these forward-looking statements.

RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress

Retrieved on: 
Thursday, September 30, 2021
Inflammation, Therapy, Viga, Asthma, Pharmacokinetics, Research, Allergic rhinitis, Skin, Patient, Risk, Congress, Atopic dermatitis, European Academy of Allergy and Clinical Immunology, Cytokine, Security (finance), U.S. Securities and Exchange Commission, Cancer, BSA, Body surface area, Psoriasis Area and Severity Index, Biomarker, AD, Itch, CEO, FRCPC, RAPT, Hives, SAN, Disease, Journal of the European Academy of Dermatology and Venereology, Ligand, Kinetics, Numerical, Sinusitis, Tissue, Eczema Area and Severity Index, Safety, Forward-looking statement, CCR4, Quality of life, Eosinophilic esophagitis, NRS, Protein, GLOBE, Pharmaceutical industry, Vaccine

We look forward to initiating our Phase 2b clinical trial in atopic dermatitis and to expanding our exploration of RPT193 in a Phase 2a trial in asthma.

Key Points: 
  • We look forward to initiating our Phase 2b clinical trial in atopic dermatitis and to expanding our exploration of RPT193 in a Phase 2a trial in asthma.
  • The Phase 1b study reported today was part of RAPTs first-in-human Phase 1a/1b trial of RPT193.
  • The Phase 1b portion of the trial was a randomized, double-blind, placebo-controlled study examining RPT193 as monotherapy in patients with moderate-to-severe AD.
  • The Phase 1a portion of the Phase 1a/1b trial was a standard single and multiple dose-escalation study in healthy volunteers.

Adastra Holdings Enters Market with Creation of THC-Free 99% Pure CBD Isolate

Retrieved on: 
Wednesday, September 29, 2021
Psilocybin, Substance-related disorder, THC, Canadian Securities Exchange, News, Review, Euphoria, LSD, Inflammation, Cannabinoid, Depression, CSE, Multimedia, Patient, Pharmacy, Oil, MDMA, Drug prohibition law, Environment, Acquisition, Legislation, FRCPC, Company, Pain, Health Canada, DMT, 5-MeO-DMT, Capsule, Distillation, Adastra, Cannabis, Schizophrenia, Research, Ageless, Anxiety, Skin, Pharmaceutical industry

The composition of CBD isolate enables the development and commercialization of recreational, medical, and cosmetic products.

Key Points: 
  • The composition of CBD isolate enables the development and commercialization of recreational, medical, and cosmetic products.
  • Designed specifically for patients and consumers seeking the benefits of CBD but in a THC-free experience, this 99% pure CBD crystalline isolate is nearly free of THC, eliminating the psychoactive effects.
  • Available in a crystalline powder, CBD isolate can be formulated into a wide range of products, including tinctures, oils, topicals, vapes, and capsules.
  • With the successful creation of a CBD isolate, we are now developing a range of medical and consumer-focused products.

RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress

Retrieved on: 
Monday, September 20, 2021
Therapy, Research, Inflammation, Risk, Security (finance), U.S. Securities and Exchange Commission, Cancer, Medical director, Patient, MD, FRCPC, Company, RAPT, Atopic dermatitis, Forward-looking statement, CCR4, Pharmaceutical industry

RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.

Key Points: 
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.
  • The Company is also pursuing a range of targets that are in the discovery stage of development.
  • Forward-looking statements include, but are not limited to, statements about the progress of RAPTs oncology and inflammation programs and the interpretation of topline results from the Phase 1b trial of RPT193.
  • RAPT disclaims any obligation to update these forward-looking statements.

Quanta Announces Formation of North American Medical Advisory Board

Retrieved on: 
Wednesday, September 1, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, San Diego Magazine, Toronto General Hospital, Peritoneal dialysis, Leadership, Biomarker, Natera, Royal college, Research, CMO, Health, Clinical Journal of the American Society of Nephrology, United Kingdom, Hypertension, Internal medicine, Medicine, University, Population health, National Kidney Foundation, ICU, Royal College of Physicians and Surgeons of Canada, Associate, CEO, Kidney disease, Genetic testing, Hospital, Freedom, American Society of Nephrology, University Health Network, Dialysis, Waste, SC, Cincinnati, United, University Hospitals Ahuja Medical Center, Chronic kidney disease, University of Pittsburgh Medical Center, MAB, Food and Drug Administration, FDA, Prescription, Physician, Society, Economics, Kidney, Kidney failure, Patient, Renal replacement therapy, FRCPC, Medical device, Pharmaceutical industry, Hemodialysis, Quanta and SC+, HEMODIALYSIS, QUANTA AND SC+

Quanta Dialysis Technologies Ltd (Quanta or the Company), a medical technology leader delivering on its vision to give control to dialysis users through more flexible and accessible dialysis care, announced today the formation of a North American Medical Advisory Board (MAB).

Key Points: 
  • Quanta Dialysis Technologies Ltd (Quanta or the Company), a medical technology leader delivering on its vision to give control to dialysis users through more flexible and accessible dialysis care, announced today the formation of a North American Medical Advisory Board (MAB).
  • The Medical Advisory Board consists of prominent nephrologists and is chaired by Dr. Paul Komenda, chief medical officer (CMO) at Quanta.
  • I am thrilled to welcome this diverse group of nephrologists who are performing at the top of their field to our North American Medical Advisory Board, said Dr. Komenda.
  • Members of Quantas North American Medical Advisory Board include:
    Dr. Christos Argyropoulos, MD: Dr. Christos Argyropoulos is the division chief of nephrology at the University of New Mexico Health Sciences Center.